The Relationship Between Serum Pentraxin 3 and Central Obesity in ST-Segment Elevation Myocardial Infarction Patients

Background and Objectives As shown in previous studies, pentraxin 3 (PTX3) can be a useful inflammatory marker for metabolic syndrome and central obesity. Serum PTX3 levels are also an independent factor associated with visceral fat area. The aim of this study was to assess the role of PTX3 as an inflammatory maker in patients with central obesity undergoing primary percutaneous coronary intervention (PCI) following an ST-segment elevation myocardial infarction (STEMI). Subjects and Methods From December 2007 to June 2008, 40 subjects (mean age: 61±11 years, M : F=34 : 6) with STEMI who underwent primary PCI were enrolled. We determined waist circumference, waist/hip ratio, body mass index (BMI), and visceral and total fat area via fat computed tomography (FAT-CT), and compared them with serum PTX3 concentrations. Results The serum PTX3 concentration was closely related to FAT-CT-estimated visceral fat area (r=0.41, p<0.01) and total fat area (r=0.38, p=0.01), respectively. The serum PTX3 concentration was not related to waist circumference (r=0.27, p=0.20), waist circumference/hip ratio (r=0.25, p=0.16), BMI (r=0.04, p=0.80) and lipid profiles, respectively. Among the parameters determining metabolic syndrome, an increasing visceral fat area had the strongest association with PTX3 concentrations. Conclusion In patients with STEMI, PTX3 is associated with central obesity and it is significantly and independently correlated with visceral fat area. FAT-CT-estimated visceral fat area is the most reliable factor associated with serum PTX3 levels in patients with STEMI and central obesity.

[1]  G. Biolo,et al.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile , 2009, Clinical and Experimental Medicine.

[2]  A. Mantovani,et al.  Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. , 2009, Atherosclerosis.

[3]  I. Kubota,et al.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. , 2007, American heart journal.

[4]  Marco Presta,et al.  Role of the soluble pattern recognition receptor PTX3 in vascular biology , 2007, Journal of cellular and molecular medicine.

[5]  J. A. Kim,et al.  Cut-off Values of Visceral Fat Area and Waist Circumference: Diagnostic Criteria for Abdominal Obesity in a Korean Population , 2006, Journal of Korean medical science.

[6]  S. Joo,et al.  Severity of Coronary Atherosclerosis; Influence of Metabolic Syndrome Risk Factor Clustering and hs-CRP , 2006 .

[7]  C. Garlanda,et al.  The long pentraxin PTX3 in vascular pathology. , 2006, Vascular pharmacology.

[8]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[9]  S. Yusuf,et al.  Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study , 2005, The Lancet.

[10]  M. Rattazzi,et al.  Innate immunity and atherogenesis , 2005, Lupus.

[11]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[12]  Gianni Tognoni,et al.  Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction , 2004, Circulation.

[13]  S. Reis,et al.  Clinical Importance of Obesity Versus the Metabolic Syndrome in Cardiovascular Risk in Women: A Report From the Women’s Ischemia Syndrome Evaluation (WISE) Study , 2004, Circulation.

[14]  Barbara Bottazzi,et al.  Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. , 2003, Vaccine.

[15]  Y. Jang,et al.  Role of Inflammation on Coronary Artery Disease in Koreans , 2002 .

[16]  A. Mantovani,et al.  Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Jong Hyun Hwang,et al.  Short-term prognostic value of CRP in the patients with acute coronary syndrome , 2000 .

[18]  G Olivetti,et al.  PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.

[19]  T. Blundell,et al.  Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. , 1996, Blood.

[20]  S. Yasuda,et al.  Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[21]  T. L. Pinto,et al.  Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. , 2006, Cardiovascular revascularization medicine : including molecular interventions.

[22]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .